Rebirth of the Strongest Tycoon

In the evening, Xia Yu summoned all the members of the acquisition team to summarize today's results and agree on tomorrow's plan according to the situation.

As soon as you come up, report the status of each group first.

Needless to say, Xia Yu's group won all of them that day.

Peter Lynch's second group is in charge of York Capital.

He reported to Xia Yuhui: "Chairman, today we negotiated with the CEO of York Capital for a day. They have agreed to sell the equity. Now the difficulty is that the price cannot be reached."

"York Capital Corp. made an offer of $55 million. Negotiations were terminated due to time constraints."

Xia Yu nodded slightly and looked at Brandon Guss, the leader of the third group, who immediately said: "Chairman, Constant Capital has great confidence in Genentech and has refused to sell the equity until the afternoon. We persuaded them to agree to sell the stake, but they offered a high price, $21.5 million for an 8.6 percent stake!"

At this price, it can be seen that their valuation of Genentech is US$250 million, which is US$50 million higher than the valuation of Coller Perkins!

But Xia Yu also expressed understanding, because from the beginning, he predicted that Constant Capital's attitude to sell equity would be the most negative.

After all, they joined in the third round of financing after defeating a lot of opponents, and they are destined to have the most confidence in Genentech.

And the latest entry means that their appetite will be the greatest. They also have the capital strength to take this risk, and the strength to wait for Genentech to go public.

Unlike the Coleiller Perkins Company, which has weak capital and has never seen a big world, Xia Yu bid a higher price and made them surrender obediently.

After gesturing Brandon Guss to sit down, Xia Yu said with a smile: "Actually, the situation is not bad. Although it didn't succeed that day, both of you successfully persuaded them to sell the equity. The difference is only in the price."

“York Capital valued Genentech at $220 million and Constant Capital at $250 million, and I was in charge of the Chrysler Perkins company I won. The valuation is only $200 million, and the gap is indeed a bit big.”

"But it doesn't matter. Constant Capital has the lowest shareholding ratio. Even if the valuation is high, it will only add one or two million dollars. Promise them!"

"You can lower the price by telling them the price of today's Claire Perkins!"

"I just have one request. Tomorrow, the acquisition must be completed. This is the company's first action. I don't want any accidents! I hope you can perform well!"

Everyone froze in their hearts and agreed in unison.

Then, continue to discuss the detailed tackling strategy, and strive to let York Capital and Conston Capital follow the pace of Polaris Capital tomorrow!

...

Early the next morning, Peter Lynch, Brandon Guss and others set off again.

Xia Yu brought his subordinates and others to Genentech.

He had not forgotten that Professor Herb Boyle wanted to see him.

And the equity in the hands of Professor Herb Boyle is also something he covets.

Xia Yu waited in the reception room for less than five minutes when he saw an old man in his fifties wearing glasses walking in.

Xia Yu saw the photo and immediately recognized that this person was Professor Herb Boyle.

He immediately got up and said hello with a little respect: "Professor Herb Boyle, hello, I am the chairman of Polaris Capital, my name is Xia Yu, you can call me Xia."

Professor Herb Boyle was not arrogant, he smiled, shook hands with Xia Yu, called Xia Yu's name awkwardly, and said, "Hello, Mr. Xia! Please take a seat!"

"Thank you, please sit down too!"

After being seated one after another, Professor Herb Boyle asked bluntly: "Mr. Xia, Robert Swanson told me yesterday that their company's equity has been sold to you, and you agreed to my conditions. , now we're just face to face,

I would like to know what is the purpose of your acquisition of Genentech? What is the attitude? "

As expected of a scientific researcher, he speaks straight and straight, but this kind of personality is just right, there are not so many troubles, as long as you touch the right door, you will actually get along very well.

Xia Yu said with a smile: "Professor Herb Boyle, the reason why we acquired Genentech is because we are very optimistic about you. We believe that your research can benefit the world, so we are willing to help you to promote your research results. To the world, and by the way, get paid some money in the process."

Xia Yu's words were very artistic. Even if Professor Herb Boyle didn't like to be flattered, the corners of his mouth were slightly raised, his complexion softened a lot, and he became a lot closer to Xia Yu.

Professor Herb Boyle squeezed out a smile and said, "Mr. Xia, if you really have this attitude, then I welcome you!"

Xia Yu nodded immediately, and the scene was very open: "Of course, we will fully support your research."

"To Professor Herb Boyle, we are very optimistic about you, so in addition to acquiring the equity of Claire Perkins, we are also acquiring the equity of York Capital and Constant Capital."

In a few simple words, Xia Yu already knew the nature of Professor Herb Boyle, so in order to avoid misunderstanding, he made things clear.

Professor Herb Boyle really didn't know the news, he frowned, stared at Xia Yu, and said bluntly: "If you buy the shares of their two companies, then the listing process of Genentech will be terminated, But the production of my research and patents requires a lot of money!"

Xia Yu looked at him calmly, and immediately said: "This is not a problem, Professor Herb Boyle, no matter how much capital you need, our Polaris Capital can inject capital! As long as you need it!"

After finishing speaking, in order to dispel Professor Herb Boyle's doubts, Xia Yu also changed his mind and said: "Professor Herb Boyle, you should actually know that listing a company has advantages, but also disadvantages. Tektronix has encountered difficulties, the stock market will transmit huge pressure to you, your plans will be subject to stricter approvals, and the spotlight of the media will always shine on you, making you unable to conduct scientific research with peace of mind!"

Xia Yu's words are very reasonable. Professor Herb Boyle has also learned about the advantages and disadvantages of the stock market in his spare time, and naturally he is also aware of past cases.

"As far as I know, Genentech is listed because the next scientific research and expansion will require a large amount of money, and now we can afford this money. I hope you can avoid being disturbed by the hustle and bustle of the outside world, and we will do our best to help you. Create a better research environment."

Professor Herb Boyle can win the Nobel Prize. Naturally, he is a person who is obsessed with experiments. If the funds required for the next expansion are not too large, the three limelight companies may not be able to afford it, and he will not be encouraged to agree. The company applies for listing.

At present, only two of his scientific research results have come out, and they are still under approval and have not yet been put into production, so the risks still exist.

Since Xia Yu's North Star Capital is willing to take over, he also hopes to continue his research.

As for the dilution of his equity after the capital injection of Polaris Capital, he doesn't care, he is not keen on money, and even he had the idea of ​​setting up a research fund with his assets after his death, for the latecomers in the DNA field. Research provides support.

There is a lot of chance and luck in his success, but not every time a goddess of luck comes, so he does not want latecomers to search for the truth because of difficult scientific research conditions.

"Mr. Xia, you are welcome to join us!"

Professor Herb Boyle said with a smile.

"Professor Herb Boyle, thank you, I believe we will get along very happily in the future!" Xia Yu said with a smile, shaking his hand again.

Professor Herb Boyle nodded with a smile: "I hope so!"

"Now the company's funds are not enough. After you complete the acquisition, I hope you can inject funds as soon as possible!"

"No problem, if the acquisition can be concluded today, then we can inject capital at any time, everything is based on your wishes!"

...

The chat between Xia Yu and Professor Herb Boyle was very pleasant, but the latter was thinking of his own experiment. After solving his doubts, he bid farewell and hurriedly returned to the laboratory.

That afternoon, the acquisitions of both groups were completed.

Among them, Peter Lynch brought out the case of the Coleiller Perkins company, and York Capital's psychological defense line collapsed at once, and finally sold 2% of its holdings at a price of 51 million US dollars. Fifteenth share transfer.

And Brandon Guss also did his best to squeeze the valuation of Genentech to $220 million.

Therefore, the 8.6 percent stake held by Constant Capital Corporation was transferred at a price of $18.92 million.

So far, Polaris Capital has spent a total of 119.92 million US dollars to acquire a 58.6% stake, becoming the largest shareholder of Genentech.

Xia Yu was very satisfied with this price.

Because he knew that the capital market was very enthusiastic about Genentech. According to the historical track, the stock price of Genentech rose from $35 to a maximum of $88 on the day it went public, and even the closing price exceeded $70. US dollar, the market value directly reached 300 million US dollars.

It is now a good deal to cut off the hustle half a year in advance, and control the valuation of Genentech to over 200 million US dollars.

Of course, if you consider Genentech's future market value of 100 billion, it will be even more worthwhile!

After completing the acquisition, Xia Yu immediately found Professor Herb Boyle to discuss the capital injection.

In order to leave a good impression, Xia Yu was not too harsh and valued the current Genentech company at 210 million US dollars.

And in order to win as much equity as possible, Xia Yu, from the perspective of Professor Herb Boyle, constantly encouraged him to develop by leaps and bounds, purchase newer and better experimental instruments, and build a top laboratory. As well as building a large factory directly.

In short, how to spend money and how to come, is to take advantage of this rare opportunity to obtain as much equity as possible.

If you don't seize the opportunity this time to be ruthless, you won't know it will be the year of the monkey next time, and the cost will be extremely scary by then!

Professor Herb Boyle was coaxed by Xia Yu, and he felt very good about Xia Yu.

In the end, a huge expansion plan was made, and the negotiation decided to inject 50 million US dollars into the company at one time!

After the capital injection, Xia Yu's shareholding ratio increased by 19.23%.

The total shareholding ratio increased to 77.83%.

And Professor Herb Boyle's shareholding ratio dropped from 4.4% to 22.17%!

At this point, Xia Yu can officially announce!

Genentech, the hunt was successful!

https://

Please remember this book's first domain name: . Apex Novel Mobile Version Reading URL: